ReviewMolecular pharmacology2026
Nanobodies unlock new mechanisms to target G protein-coupled receptors.
Review in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Once considered tools to aid structural studies, single-domain antibodies (nanobodies) have emerged as a new class of G protein-coupled receptor (GPCR) ligands. Aided by camelid immunization and advances in synthetic nanobody library development and computational design platforms, nanobody discovery has expanded to all major GPCR families. Unlike traditional small-molecule ligands, nanobodies can engage extended nonconserved extracellular epitopes to stabilize distinct receptor conformations to achieve high receptor selectivity and enable unique modes of pharmacological modulation. Integration of these properties with classical antibody engineering approaches, such as the generation of bispecific or bivalent constructs, has the potential to enable additional therapeutic strategies, such as cell and tissue-specific targeting. Recent mechanistic studies provide insight into the strategies nanobodies employ to function as agonists, antagonists, inverse agonists, and allosteric modulators. These studies begin to reveal the general principles nanobodies use to selectively engage and regulate GPCRs and uncover strategies to evolve their pharmacological properties. Continued advancements in discovery methods will expand the repertoire of nanobody ligands across additional GPCRs and deepen our mechanistic understanding to accelerate the development of the next generation of GPCR therapeutics. SIGNIFICANCE STATEMENT: G protein-coupled receptors (GPCRs) are one of the most successful targets of small-molecule drugs but are virtually untouched by antibody therapeutics. Aided by advances in discovery strategies, nanobodies have emerged as an ideal antibody scaffold to modulate GPCR signaling. Recent mechanistic studies reveal the molecular approaches nanobodies employ to target GPCRs, providing new insight into their potential as therapeutic tools. These findings provide a path toward developing nanobodies to regulate GPCR function in diverse disease contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.